Several brokerages have updated their recommendations and price targets on shares of Repligen (NASDAQ: RGEN) in the last few weeks:
- 10/8/2026 – Repligen was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
- 10/7/2026 – Repligen had its price target raised by Barclays PLC from $175.00 to $225.00. They now have an “overweight” rating on the stock.
- 9/29/2026 – Repligen had its “buy” rating reaffirmed by UBS Group AG.
- 9/28/2026 – Repligen was downgraded by Zacks Research from “strong-buy” to “hold”.
- 9/9/2026 – Repligen had its price target raised by UBS Group AG from $195.00 to $225.00. They now have a “buy” rating on the stock.
Repligen Corporation (NASDAQ:RGEN) develops and supplies bioprocessing technologies used by biopharmaceutical manufacturers to produce biological drugs, including monoclonal antibodies, recombinant proteins, vaccines and cell and gene therapies. Its products are used throughout the manufacturing process, from laboratory and process development through commercial-scale production.
The company’s portfolio includes chromatography products and protein A ligands and resins, filtration and fluid-management systems, single-use technologies, process analytics and other consumables and equipment.
See Also
- Five stocks we like better than Repligen
- ASML Can’t Keep Up With AI Demand—Why That’s a Good Thing
- Enovix’s 100,000-Battery Drone Order Sets Up a Test of Its Production Plans
- AMD’s Support Could Help Fermi Stock Overcome Its Biggest Hurdle
- Beyond the GPU: Credo Paves the Next AI Data Superhighway
Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
